10X Genomics stock jumps 3.8% on Cleveland Clinic cancer research deal

Shares of 10X Genomics rose by 3.8% after the company announced a new research partnership with Cleveland Clinic. The collaboration will focus on identifying biomarkers in bladder cancer using advanced single cell and spatial analysis technologies. Investors responded positively to the news, pushing the stock higher. The partnership will use 10X Genomics’ Flex Apex, Xenium, and newly launched Atera platforms. Scientists plan to study tumour specimens from patients with advanced bladder cancer to assess responses to antibody-drug conjugate treatments. The goal is to uncover mechanisms behind therapeutic responses not just in bladder cancer but potentially in other cancer types as well.

So far, the collaboration has no set revenue projections or commercialisation timelines. Meanwhile, corporate insiders have sold $1.8 million worth of TXG shares over the past three months, with no recorded purchases during the same period. The company currently holds a market capitalisation of around $4.03 billion and a GF Score of 69, signalling moderate long-term return expectations. The research could provide new insights into cancer treatment responses. The partnership has already boosted investor confidence, as seen in the share price increase. However, the lack of immediate financial forecasts leaves the long-term impact of the collaboration uncertain for now.